Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report)’s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.25. Hemispherx BioPharma shares last traded at $0.23, with a volume of 1,102,988 shares traded.
Hemispherx BioPharma Trading Down 6.5 %
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
See Also
- Five stocks we like better than Hemispherx BioPharma
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Moderna Shares Spike on H5N1 News—What’s Next for Investors?
- Comparing and Trading High PE Ratio Stocks
- Nebius Group (NBIS): A Small-Cap Backed by NVIDIA
- Why Invest in 5G? How to Invest in 5G Stocks
- Natural Gas Demand to Surge: Top 3 Stocks and ETFs to Consider
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
